Lymphedema after gynecological cancer treatment : Prevalence, correlates, and supportive care needs
Identifieur interne : 000460 ( PascalFrancis/Checkpoint ); précédent : 000459; suivant : 000461Lymphedema after gynecological cancer treatment : Prevalence, correlates, and supportive care needs
Auteurs : Vanessa Beesley [Australie] ; Monika Janda [Australie] ; Elizabeth Eakin [Australie] ; Andreas Obermair [Australie] ; Diana Battistutta [Australie]Source :
- Cancer [ 0008-543X ] ; 2007.
Descripteurs français
- Pascal (Inist)
- Wicri :
English descriptors
- KwdEn :
Abstract
BACKGROUND. Few studies have evaluated lymphedema after gynecological cancer treatment. The aim of this research was to establish prevalence, correlates, and supportive care needs of gynecological cancer survivors who develop lymphedema. METHODS. In 2004, a population-based cross-sectional mail survey (56% response rate) was completed by 802 gynecological cancer survivors. The questionnaire included demographic questions, a validated, generic supportive care needs measure, and a supplementary, newly developed, lymphedema needs module. RESULTS. Ten percent (95% confidence interval [CI], 8%-12%) of participants reported being diagnosed with lymphedema, and a further 15% (95% CI, 13%-17%) reported undiagnosed "symptomatic" lower limb swelling. Diagnosed lymphedema was more prevalent (36%) amongst vulvar cancer survivors. For cervical cancer survivors, those who had radiotherapy or who had lymph nodes removed had higher odds of developing swelling. For uterine and ovarian cancer survivors, those who had lymph nodes removed or who were overweight or obese had higher odds of developing swelling. Gynecological cancer survivors with lymphedema had higher supportive care needs in the information and symptom management domains compared with those who had no swelling. CONCLUSIONS. This population-based study provided evidence that lymphedema is a morbidity experienced by a significant proportion of gynecological cancer survivors and that there are considerable levels of associated unmet needs. Women at risk of lymphedema would benefit from instructions about early signs and symptoms and provision of referral information.
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
Pascal:07-0282762Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Lymphedema after gynecological cancer treatment : Prevalence, correlates, and supportive care needs</title><author><name sortKey="Beesley, Vanessa" sort="Beesley, Vanessa" uniqKey="Beesley V" first="Vanessa" last="Beesley">Vanessa Beesley</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Queensland University of Technology, School of Public Health, Institute of Health and Biomedical Innovation</s1><s2>Brisbane</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Brisbane</wicri:noRegion></affiliation></author><author><name sortKey="Janda, Monika" sort="Janda, Monika" uniqKey="Janda M" first="Monika" last="Janda">Monika Janda</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Queensland University of Technology, School of Public Health, Institute of Health and Biomedical Innovation</s1><s2>Brisbane</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Brisbane</wicri:noRegion></affiliation></author><author><name sortKey="Eakin, Elizabeth" sort="Eakin, Elizabeth" uniqKey="Eakin E" first="Elizabeth" last="Eakin">Elizabeth Eakin</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>University of Queensland, School of Population Health, Cancer Prevention Research Centre</s1><s2>Brisbane</s2><s3>AUS</s3><sZ>3 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Brisbane</wicri:noRegion></affiliation></author><author><name sortKey="Obermair, Andreas" sort="Obermair, Andreas" uniqKey="Obermair A" first="Andreas" last="Obermair">Andreas Obermair</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Royal Brisbane & Women's Hospital, Queens land Centre for Gynecological Cancer</s1><s2>Brisbane</s2><s3>AUS</s3><sZ>4 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Brisbane</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>University of Queensland, School of Medicine</s1><s2>Brisbane</s2><s3>AUS</s3><sZ>4 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Brisbane</wicri:noRegion></affiliation></author><author><name sortKey="Battistutta, Diana" sort="Battistutta, Diana" uniqKey="Battistutta D" first="Diana" last="Battistutta">Diana Battistutta</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Queensland University of Technology, School of Public Health, Institute of Health and Biomedical Innovation</s1><s2>Brisbane</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Brisbane</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">07-0282762</idno><date when="2007">2007</date><idno type="stanalyst">PASCAL 07-0282762 INIST</idno><idno type="RBID">Pascal:07-0282762</idno><idno type="wicri:Area/PascalFrancis/Corpus">000472</idno><idno type="wicri:Area/PascalFrancis/Curation">000488</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000460</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000460</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Lymphedema after gynecological cancer treatment : Prevalence, correlates, and supportive care needs</title><author><name sortKey="Beesley, Vanessa" sort="Beesley, Vanessa" uniqKey="Beesley V" first="Vanessa" last="Beesley">Vanessa Beesley</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Queensland University of Technology, School of Public Health, Institute of Health and Biomedical Innovation</s1><s2>Brisbane</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Brisbane</wicri:noRegion></affiliation></author><author><name sortKey="Janda, Monika" sort="Janda, Monika" uniqKey="Janda M" first="Monika" last="Janda">Monika Janda</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Queensland University of Technology, School of Public Health, Institute of Health and Biomedical Innovation</s1><s2>Brisbane</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Brisbane</wicri:noRegion></affiliation></author><author><name sortKey="Eakin, Elizabeth" sort="Eakin, Elizabeth" uniqKey="Eakin E" first="Elizabeth" last="Eakin">Elizabeth Eakin</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>University of Queensland, School of Population Health, Cancer Prevention Research Centre</s1><s2>Brisbane</s2><s3>AUS</s3><sZ>3 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Brisbane</wicri:noRegion></affiliation></author><author><name sortKey="Obermair, Andreas" sort="Obermair, Andreas" uniqKey="Obermair A" first="Andreas" last="Obermair">Andreas Obermair</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Royal Brisbane & Women's Hospital, Queens land Centre for Gynecological Cancer</s1><s2>Brisbane</s2><s3>AUS</s3><sZ>4 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Brisbane</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>University of Queensland, School of Medicine</s1><s2>Brisbane</s2><s3>AUS</s3><sZ>4 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Brisbane</wicri:noRegion></affiliation></author><author><name sortKey="Battistutta, Diana" sort="Battistutta, Diana" uniqKey="Battistutta D" first="Diana" last="Battistutta">Diana Battistutta</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Queensland University of Technology, School of Public Health, Institute of Health and Biomedical Innovation</s1><s2>Brisbane</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Brisbane</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">Cancer</title><title level="j" type="abbreviated">Cancer</title><idno type="ISSN">0008-543X</idno><imprint><date when="2007">2007</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Cancer</title><title level="j" type="abbreviated">Cancer</title><idno type="ISSN">0008-543X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cancer</term><term>Cancerology</term><term>Carcinoma</term><term>Epidemiology</term><term>Human</term><term>Lymphedema</term><term>Malignant tumor</term><term>Morbidity</term><term>Prevalence</term><term>Supportive care</term><term>Treatment</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Lymphoedème</term><term>Traitement</term><term>Prévalence</term><term>Tumeur maligne</term><term>Epidémiologie</term><term>Morbidité</term><term>Carcinome</term><term>Homme</term><term>Cancérologie</term><term>Cancer</term><term>Soin de support</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term><term>Cancer</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">BACKGROUND. Few studies have evaluated lymphedema after gynecological cancer treatment. The aim of this research was to establish prevalence, correlates, and supportive care needs of gynecological cancer survivors who develop lymphedema. METHODS. In 2004, a population-based cross-sectional mail survey (56% response rate) was completed by 802 gynecological cancer survivors. The questionnaire included demographic questions, a validated, generic supportive care needs measure, and a supplementary, newly developed, lymphedema needs module. RESULTS. Ten percent (95% confidence interval [CI], 8%-12%) of participants reported being diagnosed with lymphedema, and a further 15% (95% CI, 13%-17%) reported undiagnosed "symptomatic" lower limb swelling. Diagnosed lymphedema was more prevalent (36%) amongst vulvar cancer survivors. For cervical cancer survivors, those who had radiotherapy or who had lymph nodes removed had higher odds of developing swelling. For uterine and ovarian cancer survivors, those who had lymph nodes removed or who were overweight or obese had higher odds of developing swelling. Gynecological cancer survivors with lymphedema had higher supportive care needs in the information and symptom management domains compared with those who had no swelling. CONCLUSIONS. This population-based study provided evidence that lymphedema is a morbidity experienced by a significant proportion of gynecological cancer survivors and that there are considerable levels of associated unmet needs. Women at risk of lymphedema would benefit from instructions about early signs and symptoms and provision of referral information.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0008-543X</s0></fA01><fA02 i1="01"><s0>CANCAR</s0></fA02><fA03 i2="1"><s0>Cancer</s0></fA03><fA05><s2>109</s2></fA05><fA06><s2>12</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Lymphedema after gynecological cancer treatment : Prevalence, correlates, and supportive care needs</s1></fA08><fA11 i1="01" i2="1"><s1>BEESLEY (Vanessa)</s1></fA11><fA11 i1="02" i2="1"><s1>JANDA (Monika)</s1></fA11><fA11 i1="03" i2="1"><s1>EAKIN (Elizabeth)</s1></fA11><fA11 i1="04" i2="1"><s1>OBERMAIR (Andreas)</s1></fA11><fA11 i1="05" i2="1"><s1>BATTISTUTTA (Diana)</s1></fA11><fA14 i1="01"><s1>Queensland University of Technology, School of Public Health, Institute of Health and Biomedical Innovation</s1><s2>Brisbane</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>5 aut.</sZ></fA14><fA14 i1="02"><s1>University of Queensland, School of Population Health, Cancer Prevention Research Centre</s1><s2>Brisbane</s2><s3>AUS</s3><sZ>3 aut.</sZ></fA14><fA14 i1="03"><s1>Royal Brisbane & Women's Hospital, Queens land Centre for Gynecological Cancer</s1><s2>Brisbane</s2><s3>AUS</s3><sZ>4 aut.</sZ></fA14><fA14 i1="04"><s1>University of Queensland, School of Medicine</s1><s2>Brisbane</s2><s3>AUS</s3><sZ>4 aut.</sZ></fA14><fA20><s1>2607-2614</s1></fA20><fA21><s1>2007</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>2701</s2><s5>354000146791540280</s5></fA43><fA44><s0>0000</s0><s1>© 2007 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>34 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>07-0282762</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Cancer</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>BACKGROUND. Few studies have evaluated lymphedema after gynecological cancer treatment. The aim of this research was to establish prevalence, correlates, and supportive care needs of gynecological cancer survivors who develop lymphedema. METHODS. In 2004, a population-based cross-sectional mail survey (56% response rate) was completed by 802 gynecological cancer survivors. The questionnaire included demographic questions, a validated, generic supportive care needs measure, and a supplementary, newly developed, lymphedema needs module. RESULTS. Ten percent (95% confidence interval [CI], 8%-12%) of participants reported being diagnosed with lymphedema, and a further 15% (95% CI, 13%-17%) reported undiagnosed "symptomatic" lower limb swelling. Diagnosed lymphedema was more prevalent (36%) amongst vulvar cancer survivors. For cervical cancer survivors, those who had radiotherapy or who had lymph nodes removed had higher odds of developing swelling. For uterine and ovarian cancer survivors, those who had lymph nodes removed or who were overweight or obese had higher odds of developing swelling. Gynecological cancer survivors with lymphedema had higher supportive care needs in the information and symptom management domains compared with those who had no swelling. CONCLUSIONS. This population-based study provided evidence that lymphedema is a morbidity experienced by a significant proportion of gynecological cancer survivors and that there are considerable levels of associated unmet needs. Women at risk of lymphedema would benefit from instructions about early signs and symptoms and provision of referral information.</s0></fC01><fC02 i1="01" i2="X"><s0>002B04</s0></fC02><fC02 i1="02" i2="X"><s0>002B12B04</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Lymphoedème</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Lymphedema</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Linfedema</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Traitement</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Treatment</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Tratamiento</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Prévalence</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Prevalence</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Prevalencia</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Tumeur maligne</s0><s5>04</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Malignant tumor</s0><s5>04</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Tumor maligno</s0><s5>04</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Epidémiologie</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Epidemiology</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Epidemiología</s0><s5>05</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Morbidité</s0><s5>06</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Morbidity</s0><s5>06</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Morbilidad</s0><s5>06</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Carcinome</s0><s5>07</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Carcinoma</s0><s5>07</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Carcinoma</s0><s5>07</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Homme</s0><s5>08</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Human</s0><s5>08</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Hombre</s0><s5>08</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Cancérologie</s0><s5>09</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Cancerology</s0><s5>09</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Cancerología</s0><s5>09</s5></fC03><fC03 i1="10" i2="X" l="FRE"><s0>Cancer</s0><s4>CD</s4><s5>96</s5></fC03><fC03 i1="10" i2="X" l="ENG"><s0>Cancer</s0><s4>CD</s4><s5>96</s5></fC03><fC03 i1="10" i2="X" l="SPA"><s0>Cáncer</s0><s4>CD</s4><s5>96</s5></fC03><fC03 i1="11" i2="X" l="FRE"><s0>Soin de support</s0><s4>CD</s4><s5>97</s5></fC03><fC03 i1="11" i2="X" l="ENG"><s0>Supportive care</s0><s4>CD</s4><s5>97</s5></fC03><fC03 i1="11" i2="X" l="SPA"><s0>Cuidado de soporte</s0><s4>CD</s4><s5>97</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Appareil circulatoire pathologie</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Cardiovascular disease</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Aparato circulatorio patología</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Lymphatique pathologie</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Lymphatic vessel disease</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Linfático patología</s0><s5>38</s5></fC07><fN21><s1>190</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard></inist><affiliations><list><country><li>Australie</li></country></list><tree><country name="Australie"><noRegion><name sortKey="Beesley, Vanessa" sort="Beesley, Vanessa" uniqKey="Beesley V" first="Vanessa" last="Beesley">Vanessa Beesley</name></noRegion><name sortKey="Battistutta, Diana" sort="Battistutta, Diana" uniqKey="Battistutta D" first="Diana" last="Battistutta">Diana Battistutta</name><name sortKey="Eakin, Elizabeth" sort="Eakin, Elizabeth" uniqKey="Eakin E" first="Elizabeth" last="Eakin">Elizabeth Eakin</name><name sortKey="Janda, Monika" sort="Janda, Monika" uniqKey="Janda M" first="Monika" last="Janda">Monika Janda</name><name sortKey="Obermair, Andreas" sort="Obermair, Andreas" uniqKey="Obermair A" first="Andreas" last="Obermair">Andreas Obermair</name><name sortKey="Obermair, Andreas" sort="Obermair, Andreas" uniqKey="Obermair A" first="Andreas" last="Obermair">Andreas Obermair</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000460 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 000460 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PascalFrancis
|étape= Checkpoint
|type= RBID
|clé= Pascal:07-0282762
|texte= Lymphedema after gynecological cancer treatment : Prevalence, correlates, and supportive care needs
}}
| This area was generated with Dilib version V0.6.31. |  |